Ahmed M. Soliman

ORCID: 0009-0008-8632-1396 · 92 papers in corpus
rct 2024
American journal of obstetrics and gynecology ·doi:10.1016/j.ajog.2024.06.040

BACKGROUND: Elagolix, an approved oral treatment for endometriosis-associated pain, has been associated with hypoestrogenic effects when used as monotherapy. Hormonal add-back therapy has the potential to mitigate these effects. OBJECTIVE:…

observational 2023
Reproductive sciences (Thousand Oaks, Calif.) ·doi:10.1007/s43032-022-01119-2

The objective of this study was to evaluate the utility and impact of the Painful Periods Screening Tool (PPST) to improve healthcare delivery for people with symptoms of pelvic pain. The design of this study was a survey study. After IRB a…

observational 2022
BMJ open ·doi:10.1136/bmjopen-2021-052765

OBJECTIVES: To examine women's perceptions of endometriosis-associated disease burden and its impact on life decisions and goal attainment. DESIGN: An anonymous online survey was distributed in October 2018 through the social media network…

other 2021
CPT: pharmacometrics & systems pharmacology ·doi:10.1002/psp4.12570

Selection of a personalized dose for an individual patient can be informed by the patient's preferences, translated as weights on each of the clinically relevant safety and efficacy drug attributes, based on results from a brief patient pre…

other 2021
Current medical research and opinion ·doi:10.1080/03007995.2021.1929896

OBJECTIVE: Inadequate communication about endometriosis symptom burden between women and healthcare providers is a barrier for optimal treatment. This study describes the development of the EndoWheel, a patient-reported assessment tool that…

review 2021
International journal of general medicine ·doi:10.2147/IJGM.S261139

Endometriosis may exert a profound negative influence on the lives of individuals with the disorder, adversely affecting quality of life, participation in daily and social activities, physical and sexual functioning, relationships, educatio…

observational 2021
BMC women's health ·doi:10.1186/s12905-020-01139-7

BACKGROUND: Women with endometriosis are commonly treated by their sole provider. In this single-provider model of care, women frequently report long diagnostic delays, unresolved pelvic pain, multiple laparoscopic surgeries, sequential con…

observational 2020
Advances in therapy ·doi:10.1007/s12325-020-01280-7

INTRODUCTION: This retrospective cohort study evaluated the impact of endometriosis on the risks of work loss events and salary/growth over a 5-year period. METHODS: Women aged 18-49 years with ≥ 1 endometriosis diagnosis were identified i…

2020
·doi:10.1002/jbm4.10401/v2/response1
rct 2020
The journal of sexual medicine ·doi:10.1016/j.jsxm.2020.08.002

BACKGROUND: Dyspareunia experienced by women diagnosed with endometriosis is associated with a decreased health-related quality of life (HRQoL). AIM: We evaluated the relationship of clinically meaningful improvements in dyspareunia with H…

observational 2020
Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC ·doi:10.1016/j.jogc.2020.04.013

OBJECTIVE: To characterize the health-related quality of life (HRQOL) of Canadian women with a self-reported diagnosis of endometriosis (DxE). METHODS: Canadian women aged 18-49 years completed a survey from December 2018 through January 2…

review 2020
Therapeutic advances in reproductive health ·doi:10.1177/2633494120964517

While the most common symptom associated with endometriosis is pelvic pain, the systemic manifestations of the disease and the accompanying adverse psychological, emotional, social, familial, sexual, educational and workplace effects are in…

other 2020
JBMR plus ·doi:10.1002/jbm4.10401

Elagolix, a gonadotrophin-releasing hormone antagonist, is used in premenopausal women with endometriosis. There is a risk of bone loss with elagolix, but the long-term effects of BMD loss later in life cannot be directly assessed and has n…

observational 2020
Advances in therapy ·doi:10.1007/s12325-020-01361-7

INTRODUCTION: To compare all-cause and endometriosis-related healthcare resource utilization (HCRU) and healthcare costs by service categories (outpatient, inpatient, emergency room [ER], pharmacy) among patients with newly diagnosed endome…

rct 2020
Obstetrics and gynecology ·doi:10.1097/AOG.0000000000003917

OBJECTIVE: To evaluate the effects of elagolix on clinically meaningful improvements in health-related quality of life (HRQOL) measured by the EHP-30 (Endometriosis Health Profile-30). METHODS: Data from two phase III trials of elagolix fo…

observational 2020
Advances in therapy ·doi:10.1007/s12325-019-01215-x

INTRODUCTION: Endometriosis symptoms are nonspecific and overlap with other gynecologic and gastrointestinal diseases, leading to long diagnostic delays. The burden of endometriosis has been documented; however, little is known about the im…

observational 2020
Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC ·doi:10.1016/j.jogc.2020.06.022

OBJECTIVE: To evaluate fatigue burden and productivity impairments in Canadian women with a self-reported diagnosis of endometriosis (DxE). METHODS: From December 2018 to January 2019, Canadian women aged 18-49 years completed an online su…

observational 2020
Journal of comparative effectiveness research ·doi:10.2217/cer-2020-0181

Aim: To evaluate impact of co-morbidities on opioid use in endometriosis. Patients & methods: This was a retrospective analysis of data obtained from the Symphony Health database (July 2015-June 2018), which contains medical and pharmacy cl…

observational 2020
Journal of women's health (2002) ·doi:10.1089/jwh.2019.7879

Introduction: Endometriosis is a burdensome chronic condition for which conservative management is often recommended when indicated. Nonetheless, some women seek care for endometriosis in the emergency department (ED). We evaluated trends i…

other 2020
Expert review of pharmacoeconomics & outcomes research ·doi:10.1080/14737167.2021.1832468

INTRODUCTION: We evaluated elagolix and leuprolide from the patient's perspective for the treatment of endometriosis-related pain. AREA COVERED: Preference weights from a published discrete choice experiment were used to evaluate preferenc…

qualitative 2020
Journal of patient-reported outcomes ·doi:10.1186/s41687-020-00200-1

BACKGROUND: Endometriosis-related fatigue is common and negatively impacts multiple areas of many women's lives, particularly in day-to-day activities, social activities, physical activities, mood and emotions, relationships with family or …

2020
·doi:10.1016/j.jval.2020.04.245
2020
·doi:10.1016/j.jval.2020.04.281
2020
Value in Health ·doi:10.1016/j.jval.2020.04.447
2020
·doi:10.1016/j.jval.2020.04.808